TGF-β1 activating antibodies to treat graft-versus-host disease
(2026)
Files
260215_Manuscrit_These_SEW_FINAL.pdf
Open Access - Adobe PDF
- 41.82 MB
Details
- Authors
- Supervisors
- LUCAS, Sophie
- Abstract
- Graft-versus-host disease (GVHD) is a frequent and severe complication of allogeneic hematopoietic stem cell transplantation caused by uncontrolled donor T cell activity against recipient antigens. Current therapeutic options for acute and chronic GVHD are limited. Clinical approaches under development aim at enhancing immune tolerance by promoting regulatory T cell (Treg) immunosuppression. Tregs suppress other immune cells at least in part by producing active TGF-β1. We recently developed monoclonal antibodies (mAbs) that activate latent TGF-β1 and showed that they exert therapeutic effects in murine model of acute and chronic GVHD. These mAbs increase TGF-β1 activity in lymphoid organs shortly after treatment initiation, appear to improve thymic function and reduce adaptive immune responses after longer term treatment. We suggest that TGF-β1 activating mAbs may serve to treat acute or chronic GVHD in patients.
- Affiliations
Citations
Wautier, S. (2026). TGF-β1 activating antibodies to treat graft-versus-host disease. https://hdl.handle.net/2078.5/273123